Clovertex’s March Target of the Month is GSPT1, a translation termination factor that plays a vital ...
Clovertex's February Target of the Month is the farnesoid X receptor (FXR), a nuclear receptor that ...
Clovertex’s January Target of the Month is Dopamine D2 Receptor (D2R), highlighted by Johnson & John...
Clovertex’s Target of the Year 2024 is the Gastric Inhibitory Polypeptide Receptor (GIPR), which has...
Clovertex’s December Target of the Month is the Dystrophin-Glycoprotein Complex (DGC), inspired by a...
Clovertex’s November Target of the Month is Ninjurin 1 (NINJ1), selected in light of a recent cryo-E...
Following this year’s Nobel Prize in Chemistry for breakthroughs in protein structure prediction and...
We are pleased to announce that PTH1R (Parathyroid Hormone 1 Receptor) is Clovertex's Target of the ...
We are excited to announce that Isocitrate Dehydrogenase 1(IDH1) has been selected as Clovertex’s Ta...
We are excited to announce that Protective Antigen has been selected as Clovertex’s Target of the Mo...